ライフサイエンスコーパス: basal cell carcinoma

1 tate and lung adenocarcinoma to melanoma and basal cell carcinoma.

2 ncluding medulloblastoma, ameloblastoma, and basal cell carcinoma.

3 ceptor-7 agonist currently used for treating basal cell carcinoma.

4 curative surgery or radiation or metastatic basal cell carcinoma.

5 therapies for Hh-dependent cancers, such as basal cell carcinoma.

6 clinical practice for patients with advanced basal cell carcinoma.

7 nalling inhibitor, in patients with advanced basal cell carcinoma.

8 unds have been approved for use in Hh-driven basal cell carcinoma.

9 CN1 and CCN2 may provide clinical benefit in basal cell carcinoma.

10 US Food and Drug Administration for advanced basal cell carcinoma.

11 nd progression of several cancers, including basal cell carcinoma.

12 smodegib for metastatic and locally advanced basal cell carcinoma.

13 at are novel and have not been documented in basal cell carcinoma.

14 than 200,000 single cells in human blood and basal cell carcinoma.

15 inoma and reduced-intensity conditioning for basal cell carcinoma.

16 in the US and is second in incidence only to basal cell carcinoma.

17 rms of cancer, including medulloblastoma and basal cell carcinoma.

18 use of SMO antagonists for the treatment of basal cell carcinoma.

19 um antibodies and cSCC or between betaPV and basal cell carcinoma.

20 elioma, meningioma, renal cell carcinoma and basal cell carcinoma.

21 n the proliferation of colorectal cancer and basal cell carcinoma.

22 t (1 malignancy) also developed a periocular basal cell carcinoma.

23 surgical excision in patients with low-risk basal-cell carcinoma.

24 py exists for locally advanced or metastatic basal-cell carcinoma.

25 % response rate among patients with advanced basal-cell carcinoma.

26 d greater than 10% for those with metastatic basal-cell carcinoma.

27 naling are implicated in the pathogenesis of basal-cell carcinoma.

28 patients with locally advanced or metastatic basal-cell carcinoma.

29 is approved for use in adults with advanced basal-cell carcinoma.

30 nderlie the development of infundibulocystic basal cell carcinomas.

31 as well as renal, breast, lung, gastric, and basal cell carcinomas.

32 ve for select locally advanced or metastatic basal cell carcinomas.

33 d cords, and ulceration were associated with basal cell carcinomas.

34 ltiple, recurrent, locally aggressive facial basal cell carcinomas.

35 TGF-beta signaling in several cell types in basal cell carcinomas.

36 tions in Ptch1 lead to the formation of skin basal cell carcinomas.

37 rowth, with excessive signaling resulting in basal cell carcinomas.

38 ceous differentiation, including a subset of basal cell carcinomas.

39 UVR in sunlight causes mutations that drive basal cell carcinomas.

40 ehog signalling underlies the development of basal-cell carcinomas.

41 s included reduction in the size of existing basal-cell carcinomas.

42 les taken from sites of clinically regressed basal-cell carcinomas.

43 responses in locally advanced and metastatic basal-cell carcinomas.

44 the pivotal molecular abnormality underlying basal-cell carcinomas.

45 onfirmed and at least six clinically evident basal-cell carcinomas.

46 ib dosing regimens in patients with multiple basal-cell carcinomas.

47 long-term regimens in patients with multiple basal-cell carcinomas.

48 confirmed, including 9 melanomas (0.5%), 37 basal cell carcinomas (1.9%), and 1 squamous cell carcin

49 icial basal cell carcinoma, 6 weeks; nodular basal cell carcinoma, 12 weeks) or excisional surgery (4

50 types were represented in this analysis: 166 basal cell carcinomas, 146 squamous cell carcinomas, and

51 up and the placebo group with respect to new basal-cell carcinomas (20% [95% CI, -6 to 39] lower rate

52 3%]), cutaneous SCC (11 of 21 tumors [52%]), basal cell carcinoma (3 of 4 tumors [75%]), and ACC (5 o

53 (17/17) and additional TAs in SCCs (24/32), basal cell carcinomas (30/31) and malignant melanomas (1

54 o imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; nodular basal cell carcin

55 diameter) of existing clinically significant basal-cell carcinomas (-65% vs. -11%, P=0.003).

56 n lesions (8 nevi, 8 seborrheic keratoses, 7 basal cell carcinomas, 7 melanomas, 4 hemangiomas, 4 der

57 luding 55 melanocytic nevi, 20 melanomas, 15 basal cell carcinomas, 7 solar lentigines or seborrheic

58 Tumors were overwhelmingly squamous and basal cell carcinomas (73% and 24%, respectively).

59 f cutaneous squamous cell carcinomas, 95% of basal cell carcinomas, 73% of conjunctival squamous cell

60 treatment option for patients with advanced basal cell carcinoma, a population that is difficult to

61 nown about patients' experiences of advanced basal cell carcinoma (aBCC) and basal cell carcinoma nev

62 now FDA-approved for patients with advanced basal cell carcinoma, acquired mutations in Smo can resu

63 on the incidence of new surgically eligible basal-cell carcinomas after 3 months of treatment.

64 13), 499 patients (468 with locally advanced basal cell carcinoma and 31 with metastatic basal cell c

65 Tests on prostate cancer, basal cell carcinoma and breast cancer metastases to axi

66 n clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of pa

67 Hh signaling is upregulated in basal cell carcinoma and medulloblastoma and Hh pathway

68 ns in Smoothened (SMO) have been reported in basal cell carcinoma and medulloblastoma, but are largel

69 ors are clinically effective in treatment of basal cell carcinoma and medulloblastoma, but fail thera

70 ivating mutations of the Hh pathway, such as basal cell carcinoma and medulloblastoma.

71 Hh) pathway is known to drive development of basal cell carcinoma and medulloblastomas and to associa

72 re associated with an increased incidence of basal cell carcinoma and melanoma, and a nonstatisticall

73 included intradermal nevus misclassified as basal cell carcinoma and nonmelanocytic lesions (eg, seb

74 ing leads to several malignancies, including basal cell carcinoma and paediatric medulloblastoma(2).

75 Hedgehog signaling, where Ptch1 loss causes basal cell carcinoma and Ptch1;Ptch2 loss disrupts skin

76 de prior CLL for squamous cell carcinoma and basal cell carcinoma and reduced-intensity conditioning

77 up period of at least 13 years, the IRRs for basal cell carcinoma and squamous cell carcinoma remaine

78 ere noted among the 42 with locally advanced basal cell carcinoma and two (15%, 2-45) among the 13 wi

79 Approximately 75% to 80% are basal cell carcinomas and 20% to 25% are squamous cell c

80 d specificity of 89-99% for the detection of basal cell carcinomas and can potentially serve as a rap

81 Dependence of basal cell carcinomas and medulloblastomas on the Hedgeh

82 ed as nonmelanocytic (primarily as pigmented basal cell carcinomas and squamous cell carcinomas).

83 than 20% for patients with locally advanced basal-cell carcinoma and greater than 10% for those with

84 Nonmelanoma skin cancers, such as basal-cell carcinoma and squamous-cell carcinoma, are co

85 xcluded patients with morphoeic or recurrent basal-cell carcinoma and those with Gorlin syndrome.

86 study, we enrolled patients with metastatic basal-cell carcinoma and those with locally advanced bas

87 y, had serious adverse events, including two basal-cell carcinomas and one major cardiovascular adver

88 e number of new squamous-cell carcinomas and basal-cell carcinomas and the number of actinic keratose

89 treatment of actinic keratoses, superficial basal cell carcinoma, and genital warts.

90 n increased risk of squamous cell carcinoma, basal cell carcinoma, and melanoma.

91 ngioma, Hodgkin lymphoma, thyroid carcinoma, basal cell carcinoma, and parotid gland tumor, and 68.5%

92 d incidence rate ratios (IRRs) for melanoma, basal cell carcinoma, and squamous cell carcinoma by usi

93 In basal cell carcinoma, application of scATAC-seq reveals

94 Although most basal-cell carcinomas are treated surgically, no effecti

95 evelopment and some forms of cancer, such as basal cell carcinoma, are transduced by the primary cili

96 es including actinic keratosis, squamous and basal cell carcinoma as well as verruca and psoriasis an

97 ared with surgery for superficial or nodular basal cell carcinoma at low-risk sites in our noninferio

98 lly confirmed primary nodular or superficial basal-cell carcinoma at low-risk sites.

99 ndrome with at least ten surgically eligible basal-cell carcinomas at the Children's Hospital Oakland

100 baseline in the number of clinically evident basal-cell carcinomas at week 73.

101 f the variability in NMSC incidence: 82% for basal cell carcinoma (BCC) and 85% for squamous cell car

102 s in human skin biopsy samples diagnosed for basal cell carcinoma (BCC) and compared with healthy ski

103 Patients with basal cell carcinoma (BCC) and cutaneous squamous cell c

104 his method to differentiate two skin tumors, basal cell carcinoma (BCC) and Merkel cell carcinoma (MC

105 We report a case of local recurrence of basal cell carcinoma (BCC) and ocular complications foll

106 Whether susceptible people develop both basal cell carcinoma (BCC) and squamous cell carcinoma (

107 sive skin neoplasm with the features of both basal cell carcinoma (BCC) and squamous cell carcinoma (

108 Basal cell carcinoma (BCC) and squamous cell carcinoma (

109 f non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (

110 avirus (HPV) infection in the development of basal cell carcinoma (BCC) and squamous cell carcinoma (

111 mance of this methodology on differentiating basal cell carcinoma (BCC) and squamous cell carcinoma (

112 Keratinocyte cancers (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (

113 f nonmelanoma skin cancer (NMSC), defined as basal cell carcinoma (BCC) and squamous cell carcinoma (

114 tance: Keratinocyte cancers (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (

115 ng DSCMs before and after training to detect basal cell carcinoma (BCC) and squamous cell carcinoma (

116 in cancers using a population-based study of basal cell carcinoma (BCC) and squamous cell carcinomas

117 Basal cell carcinoma (BCC) are common in this age group

118 expression and its clinical significance in basal cell carcinoma (BCC) are unknown to date.

119 nacone et al. investigate the role of HPV in basal cell carcinoma (BCC) by assessing the presence of

120 The effect of UVR on human basal cell carcinoma (BCC) epidemiology is complex-the i

121 Although the number of new cases of basal cell carcinoma (BCC) has increased rapidly in the

122 elimination of superficial and early nodular basal cell carcinoma (BCC) in 2 cases using RCM imaging

123 Basal cell carcinoma (BCC) incidence is increasing, part

124 Basal cell carcinoma (BCC) incidence is increasing, part

125 Basal cell carcinoma (BCC) is characterized by frequent

126 ociation of dietary pattern with the risk of basal cell carcinoma (BCC) is little understood and has

127 Basal cell carcinoma (BCC) is the most common cancer in

128 Basal cell carcinoma (BCC) is the most common cancer wor

129 Basal cell carcinoma (BCC) is the most common malignancy

130 Basal cell carcinoma (BCC) is the most common type of sk

131 published squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) nontransplant GWAS.

132 These associations were confined to basal cell carcinoma (BCC) of the skin (rs2228529, OR 1.

133 Basal cell carcinoma (BCC) of the skin is driven by this

134 Basal cell carcinoma (BCC) of the skin is the most commo

135 Consecutively diagnosed cases of basal cell carcinoma (BCC) of the skin were histological

136 ith samples taken before diagnosis of SCC or basal cell carcinoma (BCC) of the skin were identified.

137 Basal cell carcinoma (BCC) of the skin, the most common

138 lent or aggressive, as is the case with skin basal cell carcinoma (BCC) or cerebellar medulloblastoma

139 r calcium supplementation alters the risk of basal cell carcinoma (BCC) or invasive cutaneous squamou

140 s between cigarette smoking and incidence of basal cell carcinoma (BCC) or squamous cell carcinoma (S

141 Basal cell carcinoma (BCC) represents 90% of malignant e

142 the cancer-associated microRNA-21 (miR21) in basal cell carcinoma (BCC) skin tumors.

143 (HH) signaling pathway, a crucial driver of basal cell carcinoma (BCC) tumorigenesis, and reduces BC

144 apillomavirus (HPV) DNA has been detected in basal cell carcinoma (BCC) tumors, but most epidemiologi

145 melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC)) in prospective studies simul

146 itor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinica

147 a new type of targeted therapy for advanced basal cell carcinoma (BCC), and their long-term effects,

148 ts who develop recurrent or locally advanced basal cell carcinoma (BCC), and will inevitably be integ

149 he INTU gene is aberrantly elevated in human basal cell carcinoma (BCC), coinciding with increased pr

150 cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), in part as a result of immun

151 risk estimates to evaluate the risks of SCC, basal cell carcinoma (BCC), keratinocyte cancers (KCs) o

152 ted in a variety of human cancers, including basal cell carcinoma (BCC), medulloblastoma (MB) and emb

153 ry outcomes were time to first appearance of basal cell carcinoma (BCC), squamous cell carcinoma (SCC

154 Importance: Rates of skin cancer, including basal cell carcinoma (BCC), the most common cancer, have

155 Basal cell carcinoma (BCC), the most common human cancer

156 tion exposure is the primary risk factor for basal cell carcinoma (BCC), the most common human malign

157 s directly target the genetic basis of human basal cell carcinoma (BCC), the most common of all cance

158 uence variants that confer risk of cutaneous basal cell carcinoma (BCC), we conduct a genome-wide ass

159 particularly evident in medulloblastoma and basal cell carcinoma (BCC), where inhibitors targeting t

160 This article provides an update on basal cell carcinoma (BCC), with a focus on the advanced

161 umption is associated with risk of cutaneous basal cell carcinoma (BCC).

162 verall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma (BCC).

163 treatment of locally advanced and metastatic basal cell carcinoma (BCC).

164 SC, mainly squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).

165 us cell carcinoma, and a superficial type of basal cell carcinoma (BCC).

166 moothened (SMO) inhibitor-treated metastatic basal cell carcinoma (BCC).

167 up Study, we prospectively examined risks of basal cell carcinoma (BCC, 22,786 cases), squamous cell

168 way is aberrantly activated in a majority of basal cell carcinomas (BCC).

169 procaspase-8) in association with cutaneous basal-cell carcinoma (BCC) and linked to a germline SNP

170 There is a paucity of data on basal-cell carcinoma (BCC) in the United States, since m

171 1.41 (1.19-1.67), and 1.57 (0.64-3.86), for basal cell carcinomas (BCCs) and squamous cell carcinoma

172 Basal cell carcinomas (BCCs) are diagnosed by clinical e

173 Basal cell carcinomas (BCCs) depend on Hedgehog (Hh)/Gli

174 Advanced basal cell carcinomas (BCCs) frequently acquire resistan

175 Basal cell carcinomas (BCCs) in patients with Gorlin syn

176 The incidence of basal cell carcinomas (BCCs) is increasing globally, but

177 herein affected individuals develop multiple basal cell carcinomas (BCCs) of the skin.

178 Basal cell carcinomas (BCCs) rely on Hedgehog (HH) pathw

179 Growth of basal cell carcinomas (BCCs) requires high levels of hed

180 Human basal cell carcinomas (BCCs) very frequently carry p53 m

181 However, their susceptibility to basal cell carcinomas (BCCs), a neoplasm considered orig

182 he risk of skin cancer, including melanomas, basal cell carcinomas (BCCs), and squamous cell carcinom

183 maintain maximal Hedgehog pathway output in basal cell carcinomas (BCCs), and we have previously sho

184 sting of squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs), are the most common human

185 lly all sporadic and Gorlin syndrome-related basal cell carcinomas (BCCs), with loss of function of P

186 ) have a greater risk of developing numerous basal cell carcinomas (BCCs).

187 have not, to our knowledge, been applied to basal cell carcinomas (BCCs).

188 in the skin and preventing the formation of basal cell carcinomas (BCCs).

189 ) have a greater risk of developing numerous basal cell carcinomas (BCCs).

190 e reveals that dermoscopy can help delineate basal cell carcinomas before surgical removal but that i

191 uding actinic keratoses and Bowen's disease; basal cell carcinoma; benign keratinocytic lesions inclu

192 ns are causative of Gorlin syndrome (naevoid basal cell carcinoma), but detection rates > 70% have ra

193 duced the hedgehog target-gene expression by basal-cell carcinoma by 90% (P<0.001) and diminished tum

194 c modality from which patients with advanced basal cell carcinoma can benefit substantially.

195 In some patients, all basal-cell carcinomas clinically regressed.

196 mean reduced rate of new surgically eligible basal-cell carcinomas compared with patients randomly as

197 d the development of new surgically eligible basal-cell carcinomas compared with placebo (0.4 [SD 0.2

198 on for small low-risk superficial or nodular basal-cell carcinoma dependent on factors such as patien

199 which numerous indolent, well-differentiated basal cell carcinomas develop primarily on the face and

200 Basal-cell carcinoma developed in 1 patient receiving us

201 Fewer new surgically eligible basal-cell carcinomas developed in patients receiving vi

202 Basal cell carcinomas displayed focal receptor positivit

203 We tested the anti-basal-cell carcinoma efficacy of vismodegib in a randomi

204 ma and an adenoma) and as controls on eyelid basal cell carcinomas, eyelid squamous cell carcinomas,

205 oved for treatment of patients with advanced basal cell carcinoma for whom surgery is inappropriate.

206 In skin, premalignant basal cell carcinomas form 'buds', while invasive squamo

207 oma within the tumor bed of locally advanced basal cell carcinoma found during vismodegib treatment.

208 c/hypomelanotic malignant lesions (including basal cell carcinoma) gave a 93% sensitivity and 70% spe

209 ell carcinoma tumour burden and prevents new basal-cell carcinoma growth in patients with basal-cell

210 Medicaid subjects with basal cell carcinoma had a strong, negative QOL impact a

211 -71.0) of 453 patients with locally advanced basal cell carcinoma had an overall response (153 comple

212 %; 20.7-57.7) of 29 patients with metastatic basal cell carcinoma had an overall response (two comple

213 Patients with locally advanced basal cell carcinoma had to have been deemed ineligible

214 basal cell carcinoma and 31 with metastatic basal cell carcinoma) had received study drug and had th

215 Patients with advanced basal cell carcinoma have limited treatment options.

216 (HR = 1.15, 95% CI 1.11-1.19, p < 0.001, for basal cell carcinoma; HR = 1.21, 95% CI 1.17-1.25, p < 0

217 gery remains the best treatment for low-risk basal-cell carcinoma, imiquimod cream might still be a u

218 rovide evidence that up-regulation of YAP in basal cell carcinoma impacts both aberrant keratinocyte

219 f melanoma; overall and by stage and risk of basal cell carcinoma in multivariable logistic regressio

220 ling strategy allowed objective diagnosis of basal cell carcinoma in skin tissue samples excised duri

221 Basal cell carcinoma in the very elderly were more commo

222 n, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mi

223 tance of repeated biopsy in locally advanced basal cell carcinomas in 2 clinical situations: (1) when

224 The number of basal cell carcinomas in the 5 years prior to enrollment

225 t of the signature genes for human prostatic basal cell carcinomas in the above prostate tumors.

226 ypertelorism in three patients, and multiple basal cell carcinomas in the radiation field after age 1

227 Two basal cell carcinomas in the same patient and one case o

228 odalities to help delineate tumor margins of basal cell carcinomas in the setting of Mohs micrographi

229 ular oedema in six (2%) versus six (1%), and basal-cell carcinoma in 14 (4%) versus nine (2%).

230 oma in ten (12%), asthenia in four (5%), and basal-cell carcinoma in four (5%).

231 = 9.8; 95% confidence interval = 7.7-12.3), basal cell carcinomas (incidence rate ratio = 2.5; 95% c

232 Patients with multiple basal-cell carcinomas, including those with basal-cell n

233 al, we enrolled adult patients with multiple basal-cell carcinomas, including those with basal-cell n

234 Basal-cell carcinoma is the most common form of skin can

235 er, comprising cutaneous squamous (cSCC) and basal cell carcinoma, is the most common malignancy in t

236 ecule and are indicated for locally advanced basal cell carcinoma (laBCC) and metastatic basal cell c

237 icated for the treatment of locally advanced basal cell carcinoma (laBCC), with an objective response

238 The mean number of basal-cell carcinoma lesions at week 73 was reduced from

239 rm of Smo, and abrogate the proliferation of basal cell carcinoma-like cancer cells.

240 rial Fibrillation, High Cholesterol, Asthma, Basal Cell Carcinoma, Malignant Melanoma, and Heart Atta

241 basal cell carcinoma (laBCC) and metastatic basal cell carcinoma (mBCC).

242 mouse model)-derived Hedgehog-driven tumors (basal cell carcinoma, medulloblastoma and atypical terat

243 eic keratosis, lichen planus-like keratosis, basal cell carcinomas) misclassified as melanocytic beca

244 Basal cell carcinoma (n = 8, 50%) was the most common ey

245 of advanced basal cell carcinoma (aBCC) and basal cell carcinoma nevus syndrome (BCCNS), a rare gene

246 en's Hospital Oakland Research Institute and Basal Cell Carcinoma Nevus Syndrome Life Support Network

247 Eligible patients had locally advanced basal cell carcinoma not amenable to curative surgery or

248 ose below 75 nmol l(-1) more often developed basal cell carcinoma (odds ratio (OR)=1.51 (95% confiden

249 Pretransplant basal cell carcinoma of the skin and male genital cancer

250 athway in cancer has been best documented in basal cell carcinoma of the skin.

251 th histologically confirmed locally advanced basal cell carcinoma or metastatic basal cell carcinoma

252 ed a diagnosis of and were being treated for basal cell carcinoma or squamous cell carcinoma (cases)

253 as also associated with an increased risk of basal cell carcinoma (OR, 1.19 [95% CI, 1.14-1.25], 9% f

254 ing (mean 0.6 [0.72] new surgically eligible basal-cell carcinomas per patient per year vs 1.7 [1.8]

255 lacebo (0.4 [SD 0.2] new surgically eligible basal-cell carcinomas per patient per year vs 30.0 [7.8]

256 (n=15; two [SD 0.12] new surgically eligible basal-cell carcinomas per patient per year vs 34 [1.32]

257 r year vs 30.0 [7.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

258 er year vs 34 [1.32] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

259 er year vs 1.7 [1.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

260 umber of new nonmelanoma skin cancers (i.e., basal-cell carcinomas plus squamous-cell carcinomas) dur

261 The recurrence rate of periocular nodular basal cell carcinoma (PNBCC) following treatment with im

262 d in a clinical trial testing vismodegib for basal cell carcinoma prevention (NCT00957229), using pre

263 ignancies and the squamous cell carcinoma-to-basal cell carcinoma ratio increased with time postgraft

264 The squamous cell carcinoma to basal cell carcinoma ratio was 1:3.

265 erruption of treatment, which is followed by basal-cell carcinoma recurrence.

266 lleagues and Sharpe and colleagues show that basal cell carcinomas resistant to the Smoothened (SMO)

267 e is that of a patient with locally advanced basal cell carcinoma responsive to vismodegib but with a

268 His medical history included basal cell carcinoma, rheumatoid arthritis, and Barrett

269 In patients with CLL and non-basal cell carcinoma skin cancer, mortality is as high f

270 Basal cell carcinoma, solar keratosis, and colorectal ca

271 on (aOR, 2.13; 95% CI, 1.31-3.47; P=.002) or basal-cell carcinoma specific criteria (aOR, 9.35; 95% C

272 immunosuppressed = 8.9 years), 135 (27%) had basal cell carcinoma, squamous cell carcinoma or Bowen's

273 We observed no overall increased risk for basal cell carcinoma, squamous cell carcinoma, or melano

274 scopy revealed increased tissue stiffness in basal cell carcinoma stroma compared to normal dermis.

275 In basal cell carcinoma stroma, CCN2-regulated genes type I

276 Multiple hereditary infundibulocystic basal cell carcinoma syndrome (MHIBCC) is a rare genoder

277 r sporadically or associated with the nevoid basal cell carcinoma syndrome.

278 dverse events over 24 months, which included basal-cell carcinoma (ten [3%] patients vs two [1%] pati

279 key RCM diagnostic criteria for melanoma and basal cell carcinoma that are reproducibly recognized am

280 with Gorlin syndrome with a locally advanced basal cell carcinoma that was stable while the patient w

281 nd demonstrate that BSCs likely originate as basal cell carcinomas that partially squamatize through

282 point was reduction in the incidence of new basal-cell carcinomas that were eligible for surgical re

283 , the most common pediatric brain tumor, and basal cell carcinoma, the most common cancer in the Unit

284 In 63 patients with locally advanced basal-cell carcinoma, the independently assessed respons

285 In 33 patients with metastatic basal-cell carcinoma, the independently assessed respons

286 organ transplant population at high risk for basal cell carcinoma, therapeutic options for locally ad

287 d healing, systemic lupus erythematosus, and basal cell carcinoma tumor angiogenesis.

288 edly elevated in keratinocytes in human skin basal cell carcinoma tumor islands.

289 the smoothened inhibitor vismodegib reduces basal-cell carcinoma tumour burden and prevents new basa

290 Vismodegib reduces basal-cell carcinoma tumour burden in patients with basa

291 No residual basal-cell carcinoma was detectable in 83% of biopsy sam

292 per-patient rate of new surgically eligible basal-cell carcinomas was lower with vismodegib than wit

293 advanced basal cell carcinoma or metastatic basal cell carcinoma were recruited from regional referr

294 Risk factors for basal cell carcinomas were chronic lymphocytic leukemia

295 lanomas, 29 squamous cell carcinomas, and 38 basal cell carcinomas were diagnosed, with a higher prop

296 h showed negative results for both, and from basal cell carcinomas, which showed positive receptor re

297 Patients with histologically confirmed basal cell carcinoma who received at least one dose of s

298 ll carcinoma and those with locally advanced basal-cell carcinoma who had inoperable disease or for w

299 They report an increased risk of basal cell carcinoma with tetracycline use and of squamo

300 The risk of basal cell carcinoma within nevus sebaceus appears to be